Product Code: 67606
Rising up-gradation of lifestyle coupled with the increasing demand for skin lightening is a major factor anticipated to drive the global pigmentation disorder treatment market. Additionally, increasing the aging populace, increasing incidence of skin disorders, and growing disposable income are the few other factors boosting the global pigmentation disorder treatment market. According to the Global Vitiligo Foundation, in 2017, around 70 million people across the world had vitiligo. Vitiligo is a persistent condition and very hard to treat. Furthermore, the high adoption of cosmetic procedures and skincare products is also anticipated to drive market growth during the forecast period. However, high costs and side effects associated with cosmetic procedures and unfavorable reimbursement is restraining the market growth.
Scope of the Report
Pigmentation disorders comprise a large number of diverse conditions which are usually characterized by altered melanocyte density, melanin concentration, or both, and result in altered pigmentation of the skin. Some of these disorders are very common, whereas others are rare. Pigmentation disorders are classified as hypopigmentation and hyperpigmentation. In hypopigmentation, the pigment is decreased, whereas, in depigmentation, the pigment is completely lost, leaving white skin.
Key Market Trends
Topical Treatment segment holds a significant market share
- Currently, topical treatment is dominating the global market due to the improved clinical outcomes in patients suffering from pigmentation disorders. The most common topical drugs prescribed globally are azelaic acid, hydroquinone, L-ascorbic acid, etc.
- Chemical peels have found prominence in the past decades to treat facial hyperpigmentation disorders.
- Chemical peels are the products in which a chemical solution is applied to the face, neck, and hands to exfoliate the dead skin cells, stimulate the growth of new skin cells and followed by the release of cytokines and inflammatory mediators, resulting in thickening of the epidermis, deposition of collagen, reorganization of structural elements, and increases in dermal volume.
- This process reduces solar elastosis, replaces and reorients the new dermal connective tissue, resulting in an enhanced clinical appearance of the skin, with fewer rhytides and reduced pigmentary dyschromia, and a more youthful appearance.
North America dominates the Global Pigmentation Disorders Treatment Market
- North America dominates the global pigmentation disorders treatment market owing to the rising pigmentation disorders. Presence of well-established healthcare infrastructure and major market players providing effective treatment options to the patients suffering from post-inflammatory hyperpigmentation in North America.
- According to the United Nations (UN) estimates, albinism is present in one out of 17,000 to 20,000 people in North America and Europe. In Africa one in every 5,000 to 15,000 people has albinism.
- Asia Pacific region is experiencing a swift pace in the global pigmentation disorders treatment market due to the increasing beauty consciousness among Asians, rapid entry of new players into the market and expansion by the major players into the emerging economies.
In Pigmentation Disorders Treatment market major players are focused on expanding their business in different areas by adopting various market strategies such as partnerships, collaborations, acquisitions, and mergers, etc. Key developments in the market include In July 2019, Dermatix®, a brand of A.Menarini Singapore Pte.Ltd has just launched its new acne scar care, Dermatix® Acne Scar consisting of snail slime extract and Hyaluronic Acid combating post-acne skin discoloration, the treatment gel contains Niacinamide (Vitamin B3) to reduce hyperpigmentation.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
Table of Contents
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Prevalence and of Pigmentation Disorders
- 4.2.2 Growing Expenditure on the Dermatalogical Treatments
- 4.3 Market Restraints
- 4.3.1 High Cost of the Cosmetic procedures
- 4.3.2 Inadequate Reimbursement Policies
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Type of Disorder
- 5.1.1 Albinism
- 5.1.2 Vitiligo
- 5.1.3 Melasma
- 5.1.4 Post-Inflammatory Hyperpigmentation (PIH)
- 5.1.5 Others
- 5.2 Treatment Type
- 5.2.1 Topical Treatment
- 5.2.2 Dermabrasion
- 5.2.3 Chemical peels
- 5.2.4 Laser Treatment
- 5.2.5 Phototherapy
- 5.2.6 Others
- 5.3 Geography
- 5.3.1 North America
- 184.108.40.206 United States
- 220.127.116.11 Canada
- 18.104.22.168 Mexico
- 5.3.2 Europe
- 22.214.171.124 Germany
- 126.96.36.199 United Kingdom
- 188.8.131.52 France
- 184.108.40.206 Italy
- 220.127.116.11 Spain
- 18.104.22.168 Rest of Europe
- 5.3.3 Asia Pacific
- 22.214.171.124 China
- 126.96.36.199 Japan
- 188.8.131.52 India
- 184.108.40.206 Australia
- 220.127.116.11 South Korea
- 18.104.22.168 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 22.214.171.124 GCC
- 126.96.36.199 South Africa
- 188.8.131.52 Rest of Middle East and Africa
- 5.3.5 South America
- 184.108.40.206 Brazil
- 220.127.116.11 Argentina
- 18.104.22.168 Rest of South America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Allergan, Inc
- 6.1.2 Episciences, Inc.
- 6.1.3 Dermamed Solutions
- 6.1.4 La Roche-Posay
- 6.1.5 Pierre Fabre Laboratories
- 6.1.6 SkinCeuticals International
- 6.1.7 Obagi Cosmeceuticals LLC
- 6.1.8 Alvogen, Inc.
- 6.1.9 Galderma laboratories (Nestle Skin Health S.A)
- 6.1.10 Merz Pharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS